Objective: Active or passive immunisation can mitigate plaque pathology in mur ine models of Alzheimers disease (AD). Recently, it has been shown that antibo dies against β amy loid (Aβ) are present in human immun...Objective: Active or passive immunisation can mitigate plaque pathology in mur ine models of Alzheimers disease (AD). Recently, it has been shown that antibo dies against β amy loid (Aβ) are present in human immunoglobulin preparation s (IVIgG), which specifically recognise and inhibit the neurotoxic effects of A β. This study reports the results from a pilot study using IVIgG in patients wi th AD. Methods: Five patients with AD were enrolled and received monthly IVIgG o ver a 6 month period. Efficacy assessment included total Aβ/Aβ1 42measured in the CSF/serum as well as effects on cognition (ADAS cog; CERAD) at baseline an d at 6 months following IVIgG. Results: Following IVIgG, total Aβ.levels in the CSF decreased by 30.1%(17.3 43.5%) compared to baseline (p < 0.05). Total A β.increased in the serum by 233%(p < 0.05). No significant change was found in Aβ1 42 levels in the CSF/serum. Using ADAS cog, an improvement of 3.7±2.9 p oints was detected. Scores in the MMSE were essentially unchanged (improved in f our patients, stable in one patient) following IVIgG compared to baseline. Concl usion: Although the sample size of this pilot study is too small to draw a clear conclusion, the results of this pilot study provide evidence for a more detaile d investigation of IVIgG for the treatment of AD.展开更多
抗二肽基肽酶样蛋白-6(dipeptidyl-peptidase-like protein 6,DPPX)抗体相关脑炎是自身免疫性脑炎(autoimmune encephalitis,AE)的一种罕见类型。2013年,Boronat等[1]首先报道抗DPPX抗体相关脑炎,并鉴定DPPX抗体靶标为细胞表面电压门控...抗二肽基肽酶样蛋白-6(dipeptidyl-peptidase-like protein 6,DPPX)抗体相关脑炎是自身免疫性脑炎(autoimmune encephalitis,AE)的一种罕见类型。2013年,Boronat等[1]首先报道抗DPPX抗体相关脑炎,并鉴定DPPX抗体靶标为细胞表面电压门控钾离子通道〔voltage-gated K(+)channel,Kv〕4.2胞外辅助亚基DPPX,该病典型表现为前驱期腹泻和/或体重减轻,逐渐出现认知-精神障碍,过度惊骇、肌阵挛等中枢过度兴奋和自主神经症状的“三联征”。由于Kv4.2分布广泛,可出现多个系统受累表现。本文报道作者科室诊治的2例青少年抗DPPX抗体相关脑炎病例。展开更多
文摘Objective: Active or passive immunisation can mitigate plaque pathology in mur ine models of Alzheimers disease (AD). Recently, it has been shown that antibo dies against β amy loid (Aβ) are present in human immunoglobulin preparation s (IVIgG), which specifically recognise and inhibit the neurotoxic effects of A β. This study reports the results from a pilot study using IVIgG in patients wi th AD. Methods: Five patients with AD were enrolled and received monthly IVIgG o ver a 6 month period. Efficacy assessment included total Aβ/Aβ1 42measured in the CSF/serum as well as effects on cognition (ADAS cog; CERAD) at baseline an d at 6 months following IVIgG. Results: Following IVIgG, total Aβ.levels in the CSF decreased by 30.1%(17.3 43.5%) compared to baseline (p < 0.05). Total A β.increased in the serum by 233%(p < 0.05). No significant change was found in Aβ1 42 levels in the CSF/serum. Using ADAS cog, an improvement of 3.7±2.9 p oints was detected. Scores in the MMSE were essentially unchanged (improved in f our patients, stable in one patient) following IVIgG compared to baseline. Concl usion: Although the sample size of this pilot study is too small to draw a clear conclusion, the results of this pilot study provide evidence for a more detaile d investigation of IVIgG for the treatment of AD.
文摘抗二肽基肽酶样蛋白-6(dipeptidyl-peptidase-like protein 6,DPPX)抗体相关脑炎是自身免疫性脑炎(autoimmune encephalitis,AE)的一种罕见类型。2013年,Boronat等[1]首先报道抗DPPX抗体相关脑炎,并鉴定DPPX抗体靶标为细胞表面电压门控钾离子通道〔voltage-gated K(+)channel,Kv〕4.2胞外辅助亚基DPPX,该病典型表现为前驱期腹泻和/或体重减轻,逐渐出现认知-精神障碍,过度惊骇、肌阵挛等中枢过度兴奋和自主神经症状的“三联征”。由于Kv4.2分布广泛,可出现多个系统受累表现。本文报道作者科室诊治的2例青少年抗DPPX抗体相关脑炎病例。
